Enliven Therapeutics, Inc.
ELVN
$36.96
$0.852.35%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -45.28% | 89.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -18.85% | 36.62% | |||
| Operating Income | 18.85% | -36.62% | |||
| Income Before Tax | 20.36% | -47.25% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 20.36% | -47.25% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 20.36% | -47.25% | |||
| EBIT | 18.85% | -36.62% | |||
| EBITDA | 18.78% | -36.77% | |||
| EPS Basic | 21.12% | -46.96% | |||
| Normalized Basic EPS | 21.11% | -46.94% | |||
| EPS Diluted | 21.12% | -46.96% | |||
| Normalized Diluted EPS | 21.11% | -46.94% | |||
| Average Basic Shares Outstanding | 0.94% | 0.19% | |||
| Average Diluted Shares Outstanding | 0.94% | 0.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||